The "Tumour Targeting, Imaging, Radiotherapies" network of the Cancéropôle Grand-Ouest is pleased to announce its seventeenth international workshop dedicated to young researchers (PhD students and post-docs), even so experienced researchers are invited to participate.

La Pointe de Pen Bron

The 17th edition of


“Tumour targeting, Imaging, Radiotherapies” workshop


will be held

in Erquy, West of France.



The main objective of this international workshop is to confront the points of view and issues of various research fields such as Chemistry, Biology, Physics, Medicine, Computer science, involved in the development of molecular and external beam radiotherapies in Oncology.



The 2024 topic will focus on therapeutic applications using lutetium-177, demonstrating the evolution of nuclear medicine, an initially diagnostic discipline that is now opening up to the prospect of therapeutic applications. Aspects of production, radiochemistry, dosimetry and imaging, such as pre-therapeutic SPECT imaging protocols, through to clinical trials will be discussed in the case of lutetium-177, but also for a and b emitters as alternatives. The workshop will also address the role of nanovectors for imaging and internal & external radiotherapies. Finally, the latest advances in tumor and microenvironment targeting will be highlighted.


Presentations of biologists, chemists, physicists, computer scientists and physicians will cover advances in this field of cancer research.


30 travel grant awards are available for young researchers (PhD students and post-docs).


Invited speakers in 2024:


- Richard P Baum, Professor, President of the International Centers for Precision Oncology (ICPO) Academy, Curanosticum, Center for Advanced Radiomolecular Precision Oncology, University of Frankfurt-Main, Wiesbaden-Frankfurt, Germany.


- Cristina Mueller, Professor, Research Group Leader at the Center for Radiopharmaceuti-cal Sciences (CRS), Department of Chemistry and Applied Biosciences, Paul Scherrer Institut, Zurich, Switzerland.

- Massimo Alfano, Group Leader Extracellular Microenvironment Unit, Urological Research Institute, DiBit2, Scientific Institute San Raffaele, Milan, Italy.

- Emmanuelle Liaudet Coopman, Researcher, Head of the team “Breast cancer, Microenvironment & Immunotargeting”, IRCM, Institut de Recherche en Cancérologie de Montpellier & CRLC Val d’Aurelle-Paul Lamarque, Montpellier, France.

- Miloslav Polasek, Researcher, Head of the Coordination Chemistry Research Group, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.

- Anne-Laure Bulin, Researcher, group “Cancer Targets and Experimental Therapeutics”, Institute for Advanced Biosciences, Grenoble, France.


- Lefteris Livieratos, Clinical Scientist in Nuclear Medicine, Guy’s & St Thomas’ Hospitals, King's College London, London, United Kingdom.


 The workshop will be built around lectures from the invited expert speakers and thematic sessions with selected oral presentations from young researchers providing valuable opportunities for discussion on innovative issues and highlighting integration among several disciplines.


This workshop aims at sharing scientific results and at facilitating exchanges between experienced and young researchers in the fast-growing field of imaging and radiotherapies.


In order to stimulate intense discussions between young and senior scientists, total attendance is limited to a maximum of 65 participants.



What is the "Tumour Targeting, Imaging, Radiotherapies" network of the Canceropôle Grand Ouest ?


The first "Plan Cancer" was launched in 2003 as an initiative to foster France's efforts in cancer management. One of the actions of the plan was the creation of 7 "Cancéropôles" with the mission of organizing cooperation in the field of translational research between laboratories and clinical departments within a geographic area. Thus the Cancéropôle Grand Ouest (CGO) was set-up, covering 3 of the 13 French Regions.


The CGO is now organized in 8 networks.


The "Tumour Targeting, Imaging, Radiotherapies" network includes four interconnected research domains, which are:

- Concept of innovating agents and nanomedicines for imaging and therapeutic purposes,

- Targeted therapies and radiotherapies for cancer: from animal models to clinical trials,

- Quantitative multimodal imaging and radiotherapies,

- Biological response and radiotherapies.

This network is coordinated by Dimitris Visvikis, LaTIM, National Institute of Health & Clinical Sciences, Brest, France.


More information :